RXRX
Recursion Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +4.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 77.22K | $312,175 | n/a | n/a |
| Q2 2026 | 102 | -2 | 264.93M | $972.11M | +5 | −7 |
| Q1 2026 | 107 | +3 | 243.54M | $747.81M | +9 | −7 |
| Q4 2025 | 104 | +2 | 261.79M | $1.07B | +4 | −1 |
| Q3 2025 | 16 | -2 | 173.92M | $848.75M | n/a | −3 |
| Q2 2025 | 16 | 0 | 153.65M | $777.46M | n/a | n/a |
| Q1 2025 | 13 | +3 | 87.35M | $462.12M | +3 | n/a |
| Q4 2024 | 10 | 0 | 84.02M | $567.97M | n/a | n/a |
| Q3 2024 | 9 | +2 | 69.10M | $455.38M | +2 | n/a |
| Q2 2024 | 7 | n/a | 63.72M | $477.87M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 34.82M | +7.6% | $184.17M | 1.8% | ▲ Add | 4 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 24.39M | -1.9% | $129.04M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 3 | State Street Global Advisors ✦ (passive) | 13.09M | +4.0% | $69.22M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 6.44M | +5.9% | $34.10M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 3.41M | -1.6% | $18.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 2.66M | -3.0% | $14.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.15M | -30.6% | $6.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Millennium Management ✦ | 502.11K | +1673.6% | $2.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Marshall Wace ✦ | 333.61K | New | $1.76M | 0.0% | New | 1 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 224.23K | +69.9% | $1.19M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 168.19K | New | $889,731 | 0.0% | New | 1 | SEC ↗ ×4 |
| 12 | Wellington Management ✦ | 107.48K | -6.5% | $568,548 | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 13 | D. E. Shaw & Co. ✦ | 60.91K | New | $322,193 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.76M | 0.0% |
| AQR Capital Management | $889,731 | 0.0% |
| D. E. Shaw & Co. | $322,193 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 333 holders, 334.81M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $242,000
Director · 25.00K sh · $125,000
Officer, Director · 22.41K sh · $78,822
Director · 30.00K sh · $100,200
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology